Recombinant Human Anti-CEA x Human Anti-GD2 Bispecific Antibody (Fv-IgG) (BSDG-H309)

Recombinant Anti-CEA x Anti-GD2 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CEA IgG with similar domains from an anti-GD2 antibody via short peptide linkers, or vice versa. This BsAb can bind two factors simultaneously. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CEA & GD2

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CEA

Gene ID

1048

UniProt ID

A0A024R0K5

Alternative Names

CEACAM5; carcinoembryonic antigen; carcinoembryonic antigen related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CEA x Human Anti-GD2 Bispecific Antibody (Fv-IgG) (BSDG-H309). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CEA x Human Anti-GD2 Bispecific Antibody (Fv-IgG) (CAT#: BSDG-H309)

Specifications

Targets

Customer Reviews and Q&As